Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Part 3 Specific Therapeutic Areas
- Chapter 17 Psychotropic Drug Treatment in Childhood and Adolescence
- Chapter 18 Psychotropic Drug Treatment in Later Life
- Chapter 19 Psychotropic Prescribing in Pregnancy and Lactation
- Chapter 20 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation
- Chapter 21 Antipsychotics, Weight Gain and Metabolic Risk
- Index
- References
Chapter 21 - Antipsychotics, Weight Gain and Metabolic Risk
from Part 3 - Specific Therapeutic Areas
Published online by Cambridge University Press: 29 May 2020
Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Part 3 Specific Therapeutic Areas
- Chapter 17 Psychotropic Drug Treatment in Childhood and Adolescence
- Chapter 18 Psychotropic Drug Treatment in Later Life
- Chapter 19 Psychotropic Prescribing in Pregnancy and Lactation
- Chapter 20 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation
- Chapter 21 Antipsychotics, Weight Gain and Metabolic Risk
- Index
- References
Summary
During the last 20 years there has been increased focus on the problem of premature mortality among people with schizophrenia. This has resulted in a focus on weight gain, the development of metabolic problems, the need to understand the mechanisms behind these and the need to identify strategies to manage these problems. Audit programmes have highlighted the poor quality of monitoring for, and management of, physical health problems in people with all types of mental health disorder but particularly for those with psychotic illnesses. Further, weight gain also reinforces service users’ negative views of themselves and may lead to poor adherence with treatment (Faulkner et al., 2007; Lester et al., 2011; Weiden et al., 2004).
- Type
- Chapter
- Information
- Seminars in Clinical Psychopharmacology , pp. 619Publisher: Cambridge University PressPrint publication year: 2020
References
Alberti, KGMM, Eckel, RH, Grundy, SM, et al. (2009). Harmonizing the metabolic syndrome. Circulation, 120, 1640–1645.Google Scholar
Allison, DB, Mentore, JL, Heo, M, et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 156, 1686–1696.CrossRefGoogle ScholarPubMed
Aronne, LJ, Wadden, T, Isoldi, KK, et al. (2009). When prevention fails, obesity treatment strategies. Am J Med, 122(4 Suppl 1), S24–S32.CrossRefGoogle ScholarPubMed
Arranz, B, Rosel, P, Ramirez, N, et al. (2004). Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry, 65, 1335–1342.Google Scholar
Barnes, TRE, Mutsatsa, SH, Hutton, SB, et al. (2006). Comorbid substance use and age of onset in schizophrenia: the West London first episode study. Br J Psychiatry, 188, 237–242.CrossRefGoogle Scholar
Barnes, TRE, Paton, C, Cavanagh, M-R; UK Prescribing Observatory for Mental Health (2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull, 33, 1397–1403.CrossRefGoogle ScholarPubMed
Barnes, TRE, Bhatti, SF, Adroer, R, et al. (2015). Screening for the metabolic side effects of antipsychotic medication: findings from a 6-year quality improvement programme in the UK. BMJ Open, 5, e007633.CrossRefGoogle ScholarPubMed
Barr, RS, Culhane, MA, Jubelt, LE, et al. (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology, 33, 480–490.Google Scholar
Bartoli, F, Crocamo, C, Clerici, M, et al. (2015). Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis. Eur Neuropsychopharmacol, 25, 1767–1774.Google Scholar
Bennett, ME, Wilson, AL, Genderson, M, et al. (2013). Smoking cessation in people with schizophrenia. Curr Drug Abuse Rev, 13, 180–190.Google Scholar
Bobo, WV, Cooper, WO, Stein, M, et al. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70, 1067–1075.Google Scholar
Breese, CR, Lee, MJ, Adams, CE, et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351–364.Google Scholar
Brown, S (1997). Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry, 171, 502–508.Google Scholar
Bruins, J, Jorg, F, Bruggeman, R, et al. (2014). The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders, a meta-analysis. PLoS One, 9, e112276.Google Scholar
Bushe, CJ, Slooff, CJ, Haddad, PM, Karagianis, JL (2012). Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry, 73(6), e749–e755.Google Scholar
Caemmerer, J, Correll, CU, Maayan, L (2012). Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res, 140, 159–168.Google Scholar
Chiu, C, Chen, C, Chen, B, et al. (2010). The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry, 34, 866–870.Google Scholar
Clifton, PG, Rusk, IN, Cooper, SJ (1991). Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats. Behav Neurosci, 105, 272–281.Google Scholar
Connolly, V, Unwin, N, Sherriff, P, et al. (2000). Diabetes prevalence and socioeconomic status, a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health, 54, 173–177.CrossRefGoogle ScholarPubMed
Cooper, SJ, Reynolds, GP, Barnes, TRE, et al. (2016). BAP guidelines on the management of weight gain and metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol, 30, 717–748.Google Scholar
Correll, CU, Manu, P, Olshanskiy, V, et al. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302(16), 1765–1773.CrossRefGoogle ScholarPubMed
Correll, CU, Robinson, DG, Schooler, NR (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders. JAMA Psychiatry, 71, 1350–1363.Google Scholar
Daumit, GL, Goldberg, RW, Anthony, C (2005). Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis, 193, 641–646.CrossRefGoogle ScholarPubMed
Daumit, GL, Goff, DC, Meyer, JM, et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res, 105, 175–187.Google Scholar
Daumit, GL, Dickerson, FB, Wang, N, et al. (2013). A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med, 368, 1594–1602.CrossRefGoogle ScholarPubMed
De Hert, M, Dekker, JM, Wood, D, et al. (2009a). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry, 24, 412–424.Google Scholar
De Hert, M, Schreurs, V, Vancampfort, D, et al. (2009b). Metabolic syndrome in people with schizophrenia, a review. World Psychiatry, 8, 15–22.CrossRefGoogle ScholarPubMed
De Hert, M, Correll, CU, Bobes, J, et al. (2011). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 10, 52–77.Google Scholar
Deng, C, Lian, J, Pai, N, et al. (2012). Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol, 26, 1271–1279.Google Scholar
Department of Health (2016). Alcohol Guidelines Review – report from the guidelines development group to the UK Chief Medical Officers. London: Department of Health. Available at: www.gov.uk/government/consultations/health-risks-from-alcohol-new-guidelines (last accessed 16.8.19).Google Scholar
Dombrowsi, SU, Avenell, A, Sniehotta, FF (2010). Behavioural interventions for obese adults with additional risk factors for morbidity: systematic review of effects on behaviour, weight and disease risk factors. Obes Facts, 3, 377–396.Google Scholar
Druss, BG, Von Esenwein, SA, Glick, GE, et al. (2017). Randomized trial of an integrated behavioral health home: the Health Outcomes Management and Evaluation (HOME) study. Am J Psychiatry, 174(3), 246–255.Google Scholar
Fan, X, Borba, CPC, Copeland, P, et al. (2013). Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand, 127, 217–226.CrossRefGoogle ScholarPubMed
Faulkner, G, Cohn, T, Remington, G, et al. (2007). Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res, 90, 174–178.Google Scholar
Fernandez-Sola, J (2015). Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol, 12, 576–587. doi:10.1038/nrcardio.2015.91.CrossRefGoogle ScholarPubMed
Fleischhacker, WW, Heikkinen, ME, Olie, J-P, et al. (2010). Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine, a randomized, double-blind, placebo-controlled trial. Int J Psychopharmacol, 13, 1115–1125.Google Scholar
Fleischhacker, WW, Siu, CO, Bodén, R, et al.; EUFEST study group (2013). Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Psychopharmacol, 16, 987–995.Google Scholar
Foley, DL, Morley, KI (2011). Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry, 68, 609–616.Google Scholar
Gafoor, R, Booth, P, Gulliford, MC (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ, 361, k1951. http://dx.doi.org/10.1136/bmj.k1951.Google Scholar
Gilbody, S, Peckham, E, Man, M-S, et al. (2015). Bespoke smoking cessation for people with severe mental ill health (SCIMITAR), a pilot randomised controlled trial. Lancet Psychiatry, 2, 395–402.Google Scholar
Hamoui, N, Kingsbury, S, Anthone, GJ, et al. (2004). Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg, 14, 349–352.CrossRefGoogle ScholarPubMed
Hasan, A, Falkai, P, Wobrock, T, et al. (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: part 2, update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry, 14, 2–44.Google Scholar
Hegedűs, C, Kovacs, D, Kiss, R, et al. (2015). Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague–Dawley rats. J Psychopharmacol, 29, 1271–1279.Google Scholar
Henderson, DC, Cagliero, E, Copeland, PM, et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry, 62, 19–28.Google Scholar
Henderson, DC, Kunkel, L, Nguyen, DD, et al. (2006). An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand, 113, 142–147.Google Scholar
Henderson, DC, Fan, X, Copeland, PM, et al. (2009). Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol, 29, 165–169.Google Scholar
Hermes, E, Nasrallah, H, Davis, V, et al. (2011). The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res, 128, 166–170.Google Scholar
Hickling, LM, Perez-Iglesias, R, McNeill, A, et al. (2018). A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness. Psychol Med, 49, 1033–1040. https://doi.org/10.1017/S0033291718001782.Google Scholar
Hippisley-Cox, J, Coupland, C, Brindle, P (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ, 357, j2099.Google Scholar
Hjorthoj, C, Østergaard, ML, Benros, ME, et al. (2015). Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry, 2(9), 801–808.Google Scholar
Holt, RI, Mitchell, AJ. (2015). Diabetes mellitus and severe mental illness, mechanisms and clinical implications. Nat Rev Endocrinol, 11, 79–89.Google Scholar
Holt, RI, Gossage-Worrall, R, Hind, D, et al. (2019). Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry, 214, 63–73.Google Scholar
Hommel, JD, Trinko, R, Sears, RM, et al. (2006). Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron, 51, 801–810.Google Scholar
Hunt, GE, Siegfried, N, Morley, K, et al. (2013). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev, (10), CD001088. doi:10.1002/14651858.CD001088.pub3.Google Scholar
InterAct Consortium (2014). Smoking and long-term risk of type 2 diabetes, the EPIC-InterAct study in European populations. Diabetes Care, 37, 3164–3171.CrossRefGoogle Scholar
Ishøy, PL, Knop, FK, Broberg, BV, et al. (2017). Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial. Diabetes Obes Metab, 19, 162–171.Google Scholar
Jarskog, LF, Hamer, RM, Catellier, DJ, et al.; METS Investigators (2013). Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry, 170, 1032–1040.Google Scholar
Jin, H, Meyer, J, Mudaliar, S, et al. (2008). Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res, 100, 70–85.Google Scholar
Johnson, DE, Yamazaki, H, Ward, KM, et al. (2005). Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes, 54, 1552–1558.Google Scholar
Kahn, RS, Fleischhacker, WW, Boter, H (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder, an open randomised clinical trial. Lancet, 371, 1085–1097.Google Scholar
Kelly, C, McCreadie, R (2000). Cigarette smoking and schizophrenia. Adv Psychiatr Treat, 6, 327–331.Google Scholar
Kim, SF, Huang, AS, Snowman, AM, et al. (2007). From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A, 104, 3456–3459.Google Scholar
Kinon, BJ, Kaiser, CJ, Ahmed, S (2005). Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol, 25, 255–258.CrossRefGoogle ScholarPubMed
Kirk, SL, Neill, JC, Jones, DN, et al. (2004). Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol, 505, 253–254.Google Scholar
Kirk, SL, Glazebrook, J, Grayson, B, et al. (2009). Olanzapine-induced weight gain in the rat, role of 5-HT2C and histamine H1 receptors. Psychopharmacology, 207, 119–125.Google Scholar
Kodama, S, Horikawa, C, Fujihara, K, et al. (2014). Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev, 15, 202–214.Google Scholar
Koskinen, J, Löhönen, J, Koponen, H, et al. (2009). Prevalence of alcohol use disorders in schizophrenia – a systematic review and meta-analysis. Acta Psychiatr Scand, 120, 85–96.Google Scholar
Kramer, CK, Leitao, C, Pinto, LC, et al. (2011). Efficacy and safety of topiramate on weight loss, a meta-analysis of randomized controlled trials. Obes Rev, 12, e338–e347. doi:10.1111/j.1467-789X.2010.00846.x.Google Scholar
Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28, 519–526.Google Scholar
Kroon, LA (2007). Drug interactions with smoking. Am J Health Syst Pharm, 64(18), 1917–1921.CrossRefGoogle ScholarPubMed
Larsen, JR, Vedtofte, L, Jakobsen, MSL, et al. (2017). Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder a randomized clinical trial. JAMA Psychiatry, 74, 719–728.Google Scholar
Lawrence, D, Hancock, KJ, Kisely, S (2013). The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ, 346, f2539.CrossRefGoogle ScholarPubMed
Lester, H, Marshall, M, Jones, P, et al. (2011). Views of young people in early intervention services for first-episode psychosis in England. Psychiatr Serv, 62, 882–887.Google Scholar
Leucht, S, Cipriani, A, Spineli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951–962.Google Scholar
Lingford-Hughes, AR, Welch, S, Peters, L, et al. (2012). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity, recommendations from BAP. J Psychopharmacol, 26, 899–952.CrossRefGoogle ScholarPubMed
Manu, P, Dima, L, Shulman, M (2015). Weight gain and obesity in schizophrenia, epidemiology, pathobiology, and management. Acta Psychiatr Scand, 132, 97–108.Google Scholar
Matsui-Sakata, A, Ohtani, H, Sawada, Y (2005). Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet, 20, 368–378.Google Scholar
McCreadie, RG; Sottish Schizophrenia Lifestyle Group (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry, 183, 534–539.Google Scholar
McManus, S, Bebbington, P, Jenkins, R, Brugha, T (eds.) (2016). Adult Psychiatric Morbidity Survey: Mental Health and Wellbeing, England, 2014. Leeds: NHS Digital.Google Scholar
McQuade, RD, Stock, E, Marcus, R, et al. (2004). A comparison of weight change during treatment with olanzapine or aripiprazole, results from a randomised, double-blind study. J Clin Psychiatry, 65, 47–56.Google Scholar
Meyer, JM, Davis, VG, McEvoy, JP, et al. (2008). Impact of antipsychotic treatment on non-fasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res, 103, 104–109.Google Scholar
Minutolo, G, Caponnetto, P, Auditore, R, et al. (2013). Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. Eur Neuropsychopharmacol, 23(Suppl 2), S581–S582.Google Scholar
Mitchell, AJ, Malone, D, Doebbeling, CC (2009). Quality of medical care for people with and without comorbid mental illness and substance misuse, systematic review of comparative studies. Br J Psychiatry, 194, 491–499.Google Scholar
Mitchell, AJ, Vancampfort, D, DeHerdt, A, et al. (2013a). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull, 39, 295–305.Google Scholar
Mitchell, AJ, Vancampfort, D, Sweers, K, et al. (2013b). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A review and meta-analysis. Schizophr Bull, 39, 306–318.Google Scholar
Mizuno, Y, Suzuki, T, Nakagawa, A, et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia, a systematic review and meta-analysis. Schizophr Bull, 40, 1385–1403.Google Scholar
Mothi, SS, Tandon, N, Padmanabhan, J, et al. (2015). Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. Schizophr Res, 165, 103–107.Google Scholar
Mukundan, A, Faulkner, G, Cohn, T, et al. (2010). Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev, (12), CD006629. doi:10.1002/14651858.CD006629.pub2.Google Scholar
Muscatello, MRA, Bruno, A, Pandolfo, G, et al. (2011). Effect of aripiprazole augmentation of clozapine in schizophrenia, a double-blind, placebo-controlled study. Schizophr Res, 127, 93–99.CrossRefGoogle ScholarPubMed
Myles, N, Newall, HD, Curtis, J, et al. (2012). Tobacco use before, at, and after first-episode psychosis, a systematic meta-analysis. J Clin Psychiatry, 73, 468–475.Google Scholar
National Institute for Health and Care Excellence (NICE) (2008). Stop smoking services. Public health guideline [PH10]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2011). Alcohol-use disorders, diagnosis, assessment and management of harmful drinking and alcohol dependence. Clinical guideline [CG115]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2012). Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. Public health guideline [PH38]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014a). Psychosis and schizophrenia in adults, prevention and management. Clinical guideline [CG178]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014b). Cardiovascular disease: risk assessment and reduction. Clinical guideline [CG181]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014c). Bipolar disorder, assessment and management. Clinical guideline [CG185]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014d). Obesity, identification, assessment and management. Clinical guideline [CG189]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2015). Type 2 diabetes in adults: management. NICE guideline [NG28]. London: National Institute for Health and Care Excellence.Google Scholar
Newcomer, JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(Suppl 1), 1–93.CrossRefGoogle ScholarPubMed
Newcomer, JW, Haupt, DW, Fucetola, R, et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry, 59, 337–345.Google Scholar
Olfson, M, Gerhard, T, Huang, C (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72, 1172–1181.Google Scholar
Osborn, DPJ, Levy, G, Nazareth, I, et al. (2007a). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s general practice research database. Arch Gen Psychiatry, 64, 242–249.Google Scholar
Osborn, DP, Nazareth, I, King, MB (2007b). Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness, a cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol, 42, 787–793.Google Scholar
Osborn, D, Hardoon, S, Omar, RZ, et al. (2015). Cardiovascular risk prediction models for people with severe mental illness. Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry, 72, 143–151.Google Scholar
Padmanabhan, JL, Nanda, P, Tandon, N, et al. (2016). Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives. J Psychiatr Res, 77, 52–58.Google Scholar
Perry, BI, McIntosh, G, Weich, S, et al. (2016). The association between first-episode psychosis and abnormal glycaemic control, systematic review and meta-analysis. Lancet Psychiatry, 3, 1049–1058.Google Scholar
Petrakis, IL, Nich, C, Ralevski, E (2006). Psychotic spectrum disorders and alcohol abuse, a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull, 32, 644–654.Google Scholar
Pillinger, T, Beck, K, Gobjila, C, et al. (2017). Impaired glucose homeostasis in first-episode schizophrenia, a systematic review and meta-analysis. JAMA Psychiatry, 74, 261–269.Google Scholar
Pratt, SI, Sargent, J, Daniels, L, et al. (2016). Appeal of electronic cigarettes in smokers with serious mental illness. Addict Behav, 59, 30–34.Google Scholar
Reynolds, GP (2012). The pharmacogenetics of antipsychotic drug-induced weight gain – a critical review. Clin Psychopharmacol Neurosci, 10, 71–77.Google Scholar
Reynolds, GP, Kirk, SL (2010). Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol Ther, 125, 169–179.Google Scholar
Reynolds, GP, McGowan, O (2017). Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. J Psychopharmacol, 31, 1430–1436. https//doi.org/10.1177/026988111772.Google Scholar
Reynolds, GP, Dalton, C, Watrimez, W, et al. (2019). Adjunctive lurasidone suppresses food intake and weight gain associated with olanzapine administration in rats. Clin Psychopharmacol Neurosci, 17, 314–317.Google Scholar
Roffeei, SN, Reynolds, GP, Zainal, NZ, et al. (2014). Association of ADR2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole and ziprasidone. Hum Psychopharmacol, 29, 38–45.Google Scholar
Royal College of Psychiatrists (2012). Report of the National Audit of Schizophrenia (NAS) 2012. London: Healthcare Quality Improvement Partnership.Google Scholar
Royal College of Psychiatrists (2014). Report of the second round of the National Audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership.Google Scholar
Royal College of Psychiatrists (2018). National Clinical Audit of Psychosis – National report for the core audit 2018. London: Healthcare Quality Improvement Partnership. Available at: www.rcpsych.ac.uk/docs/default-source/improving-care/ccqi/national-clinical-audits/ncap-library/ncap-national-report-for-core-audit-2018.pdf?sfvrsn=23c6a262_2 (last accessed 16.8.19).Google Scholar
Rummel-Kluge, C, Komossa, K, Schwarz, S, et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia, a systematic review and meta-analysis. Schizophr Res, 123, 225–233.Google Scholar
Ryan, MC, Collins, P, Thakore, JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry, 160, 284–289.Google Scholar
Sengupta, S, Parrilla-Escobar, MA, Klink, R, et al. (2008). Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr Res, 102, 329–336.Google Scholar
Shiers, DE, Rafi, I, Cooper, SJ, Holt, RIG (2014). Positive Cardiometabolic Health Resource, an intervention framework for patients with psychosis and schizophrenia. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version). London: Royal College of Psychiatrists. Available at: www.rcpsych.ac.uk/workinpsychiatry/qualityimprovement/nationalclinicalaudits/nationalschizophreniaaudit/nasresources.aspx.Google Scholar
Simon, V, van Winkel, R, De Hert, M (2009). Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry, 70, 1041–1050.Google Scholar
Snigdha, S, Thumbi, C, Reynolds, GP, et al. (2008). Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol, 22, 567–571.Google Scholar
Spelman, LM, Walsh, PI, Sharifi, N, et al. (2007). Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetes Med, 24, 481–485.Google Scholar
Speyer, H, Christian Brix Nørgaard, H, Birk, M, et al. (2016). The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry, 15(2), 155–165.Google Scholar
Stahl, SM, Cucchiaro, J, Simonelli, D, et al. (2013). Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry, 74, 507–515.Google Scholar
Stokes, C, Peet, M (2004). Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci, 7, 247–249.Google Scholar
Tagami, K, Kashiwase, Y, Yokoyama, A, et al. (2016). The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: an in vitro study with cells expressing cloned human growth hormone secretagogue receptor. Neuropeptides, 58, 93–101.Google Scholar
Taylor, D, Paton, C, Kapur, S (2012). The Maudsley Prescribing Guidelines in Psychiatry, 11th ed. London: Wiley Blackwell.Google Scholar
Teasdale, SB, Ward, PB, Rosenbaum, S, et al. (2017). Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in sevmental illness. Br J Psychiatry, 210, 110–118.Google Scholar
Tidey, JW, Miller, ME (2015). Smoking cessation and reduction in people with chronic mental illness. BMJ, 351, h4065.Google Scholar
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia, a population-based cohort study (FIN11 study). Lancet, 374, 620–627.Google Scholar
Toalson, P, Ahmed, S, Hardy, T, et al. (2004). The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry, 6, 152–158.Google Scholar
Vancampfort, D, Wampers, M, Mitchell, AJ, et al. (2013). A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry, 12, 240–250.Google Scholar
Vandenberghe, F, Gholam-Rezaee, M, Saigí-Morgui, N (2015). Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry, 76, e1417–e1423.Google Scholar
Wang, H, Peng, D-Q (2011). New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis, 10, 176. https://doi.org/10.1186/1476-511X-10–176.Google Scholar
Weiden, PJ, Mackell, JA, McDonnell, DD (2004). Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res, 66, 51–57.Google Scholar
Weiden, PJ, Newcomer, JW, Loebel, AD, et al. (2008). Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology, 33, 985–994.Google Scholar
Williams, JM, Foulds, J (2007). Successful tobacco dependence treatment in schizophrenia. Am J Psychiatry, 164, 222–227.Google Scholar
World Health Organization (2010). Hidden cities: unmasking and overcoming health inequities in urban settings. Geneva: WHO Press.Google Scholar
Wu, RR, Jin, H, Gao, K, et al. (2012). Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia, a double-blind, randomized, placebo-controlled study. Am J Psychiatry, 169, 813–821.Google Scholar
Yevtushenko, OO, Cooper, SJ, O’Neill, R, et al. (2008). Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry, 192, 424–428.Google Scholar
Zhang, JP, Lencz, T, Zhang, RX, et al. (2016). Pharmacogenetic associations of antipsychotic drug-related weight gain, a systematic review and meta-analysis. Schizophr Bull, 42, 1418–1437.Google Scholar
Zhang, ZJ, Yao, ZJ, Liu, W, et al. (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry, 184, 58–62.Google Scholar
Zhu, Y, Krause, M, Huhn, M, et al. (2017). Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry, 4(9), 694–705.Google Scholar